Expert review demonstrates apolipoprotein B outperforms traditional lipid markers in predicting cardiovascular risk, indicating a clearer target for atherogenic assessment.
Apolipoprotein B unifies, amplifies, and simplifies the information from the conventional lipid markers as to the atherogenic risk attributable to the apoB lipoproteins.
No takes yet. Share an insight, caveat, or question.
Sniderman et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: